Athyroidal Hypothyroidism with Spiky Hair and Cleft Palate Syndrome

Athyroidal hypothyroidism with spiky hair and cleft palate syndrome is a very rare genetic disorder in which a baby is born without a thyroid gland (athyr(e)osis) or with a severely under-developed thyroid. Because the thyroid is missing, the body cannot make thyroid hormone. This causes congenital hypothyroidism from birth. Children also commonly have a cleft palate (an opening in the roof of the mouth) and spiky or coarse hair. Many cases are caused by changes (variants) in a gene called FOXE1 (also called TTF-2). This condition is also known as Bamforth–Lazarus syndrome. Early treatment with levothyroxine (L-T4) lets most children grow and develop well, while cleft-palate and airway features are managed by ENT and craniofacial teams. PubMed+3National Organization for Rare Disorders+3Orpha+3

Bamforth–Lazarus syndrome. It is a genetic, autosomal-recessive disorder linked to changes in the FOXE1 gene. Children are born with congenital hypothyroidism (usually because the thyroid gland did not form at all), a cleft palate, and spiky hair. Some babies also have choanal atresia (blocked back of the nose) and a bifid epiglottis. Early diagnosis and thyroid hormone treatment can prevent most long-term problems from low thyroid levels. GARD Information Center+2NCBI+2

Why FOXE1 matters: FOXE1 controls key steps in building the thyroid and the palate before birth. Harmful variants (usually autosomal recessive) disrupt normal thyroid formation and palate closure, explaining the combination of athyreosis, cleft palate, choanal atresia in some patients, and characteristic hair. Animal and human studies support this biology. PubMed+2Frontiers+2

---

Other names

This syndrome appears in the medical literature under several names. Knowing these names helps you find the right resources:

• Bamforth–Lazarus syndrome (the most common medical name). Orpha

• Athyroidal hypothyroidism–spiky hair–cleft palate syndrome (a descriptive synonym that lists the three key features). Wikipedia

• Bamforth syndrome or Hypothyroidism–cleft palate syndrome (short forms sometimes used by rare-disease groups and catalogs). Global Genes

All of these names refer to the same underlying disorder linked to FOXE1. Liebert Publishing

Bamforth–Lazarus syndrome is a very rare inherited condition that affects the way the thyroid gland and parts of the face and throat develop before birth. The thyroid gland often does not form at all (this is called athyreosis), so babies are born with low thyroid hormone (congenital hypothyroidism). Many children also have a cleft palate, which is a gap in the roof of the mouth, and spiky, coarse hair. In some children, the back of the nose is blocked (choanal atresia), and the upper part of the voice box is split into two (bifid epiglottis). The cause is usually two faulty copies of the FOXE1 gene (one from each parent). This gene helps guide early development of the thyroid and palate. GARD Information Center+2NCBI+2

---

Types

There is only one core genetic syndrome, but doctors sometimes describe clinical “types” based on which features are present. These labels can help plan care:

1. Classic form – congenital hypothyroidism with athyreosis, cleft palate, and spiky hair. This is the most typical pattern. Orpha

2. Classic-plus airway form – the classic features plus choanal atresia and/or bifid epiglottis, which may cause early feeding or breathing trouble. GARD Information Center

3. Variable thyroid form – thyroid tissue is present but small or displaced (thyroid hypoplasia or ectopia) rather than completely absent; children still have congenital hypothyroidism and need treatment. NCBI

4. Mild palate-dominant form – palate and hair findings are obvious, but hypothyroidism is found mainly by newborn screening and lab tests, not by symptoms. (This reflects variability in how strongly the gene change shows itself.) Frontiers

These “types” are descriptive only; they do not change the genetic diagnosis (FOXE1-related) or the need to replace thyroid hormone.

---

Causes

Here, “causes” means biologic reasons and pathways that lead to the syndrome or increase the chance of it appearing in a child. Some are direct (mutations), some are genetic mechanisms that make mutations more likely to be inherited together, and some are proposed modifiers that explain why severity differs among families.

1. Biallelic loss-of-function variants in FOXE1 (both copies faulty) – the main cause of the syndrome. PubMed

2. FOXE1 missense mutations – a single letter change that alters the protein; several families have been reported. Liebert Publishing

3. FOXE1 frameshift or nonsense mutations – changes that truncate the protein and prevent normal function. PubMed

4. Autosomal-recessive inheritance – a child gets one non-working copy from each parent, who are usually healthy carriers. Karger Publishers

5. Consanguinity (parents related) – increases the chance both parents carry the same rare FOXE1 variant. Karger Publishers

6. Uniparental isodisomy – very rare situation where a child inherits two copies of one parent’s chromosome segment with a FOXE1 variant, leading to homozygosity. Karger Publishers

7. FOXE1 polyalanine tract variation – differences in a repeat region may modify thyroid development and help explain variable severity (research is ongoing). Frontiers

8. Regulatory-region or promoter variants near FOXE1 – changes outside the coding sequence may reduce gene expression (suggested by genetic studies). Frontiers

9. Small deletions/duplications at 9q22.33 (FOXE1 locus) – structural changes can disrupt gene function (reported in gene curation datasets). search.clinicalgenome.org

10. Compound heterozygosity – two different pathogenic variants in FOXE1, one on each copy of the gene. Liebert Publishing

11. Altered FOXE1 targets during development – FOXE1 helps regulate MSX1 and TGF-β3, important for palate fusion; disruption can contribute to clefting. Wikipedia

12. Interaction with other thyroid-development genes (e.g., PAX8, NKX2-1) – not primary causes of this syndrome, but background variation may modify the phenotype (inference from CH biology). Frontiers

13. Ectopic/absent thyroid primordium because the embryonic migration program guided by FOXE1 fails. ScienceDirect

14. Defective epithelial-mesenchymal signaling in the palate caused by reduced FOXE1 activity, leading to cleft palate. Wikipedia

15. Embryonic airway patterning problems affecting the epiglottis and choanae when FOXE1 is non-functional. GARD Information Center

16. Gene dosage sensitivity – when both copies are non-functional, the full syndrome appears; single-copy carriers are usually unaffected. Karger Publishers

17. Epigenetic influences that change how strongly FOXE1 and its targets are expressed (suggested by experimental models). Frontiers

18. Population founder effects – in some communities, a single ancestral FOXE1 variant may be more common, increasing local case numbers (reported across recessive disorders; noted in some FOXE1 families). Karger Publishers

19. Environmental modifiers of thyroid development – environment does not cause this syndrome, but maternal factors can influence thyroid organogenesis in general; they may modify presentation when a FOXE1 mutation is present (research context). Frontiers

20. Random developmental variation – even with the same FOXE1 variants, severity can differ between siblings, reflecting natural variability in early development. Frontiers

---

Common symptoms and signs

1. Newborn hypothyroidism – babies may be sleepy, feed poorly, feel cool, or look puffy; sometimes screening finds it before symptoms. Early treatment prevents brain injury. GARD Information Center

2. Cleft palate – a gap in the roof of the mouth causes nasal-sounding cry, milk leaking from the nose, and frequent ear infections; surgery restores the palate. Orpha

3. Spiky, coarse hair – hair shafts stand out and look stiff; this is harmless but is a helpful clinical clue. Orpha

4. Choanal atresia – blocked nasal passages cause noisy breathing or cyanosis during feeding; urgent airway care may be needed. GARD Information Center

5. Bifid epiglottis – a split epiglottis may contribute to stridor, swallowing issues, or aspiration in infancy. GARD Information Center

6. Jaundice that lasts – low thyroid slows clearing of bilirubin, so newborn jaundice may persist. GARD Information Center

7. Large tongue (macroglossia) and hoarse cry – classic signs of congenital hypothyroidism that improve with treatment. GARD Information Center

8. Constipation and feeding difficulty – slow gut movement and cleft palate both make feeding harder without support. GARD Information Center

9. Dry, cool skin and low temperature – reflect a slow metabolism. GARD Information Center

10. Umbilical hernia – often seen with hypothyroidism in infants. GARD Information Center

11. Poor growth – untreated hypothyroidism slows growth; thyroid hormone replacement normalizes it. GARD Information Center

12. Developmental delay (preventable) – delay can occur if hypothyroidism is not treated early; prompt levothyroxine usually prevents this. GARD Information Center

13. Recurrent ear problems – fluid in the middle ear is common with cleft palate and may affect hearing. AccessPediatrics

14. Feeding-related choking or nasal regurgitation – linked to the cleft and choanal atresia; specialized bottles and early surgery help. AccessPediatrics

15. Facial differences – some children have subtle facial features or, rarely, brain cavities (porencephaly) reported in isolated cases. GARD Information Center

Diagnostic tests

A) Physical examination

1. Full newborn exam with thyroid focus – doctors check for signs of low thyroid (puffy face, large tongue, hoarse cry) and measure growth. This is the first clue and guides urgent thyroid testing. GARD Information Center

2. Inspection of the palate – a headlight and tongue depressor can reveal a cleft or a submucous cleft; this immediately triggers referral to a cleft team. Orpha

3. Nasal patency check – misting on a mirror or fog on cotton wool under the nostrils helps quickly screen for choanal blockage. It is simple and rapid at the bedside. AccessPediatrics

4. Airway and voice assessment – stridor, weak/hoarse cry, or aspiration signs raise concern for a bifid epiglottis or laryngeal anomalies. GARD Information Center

5. Hair and skin survey – the typical spiky hair supports the clinical impression when seen with a cleft and hypothyroidism. Orpha

B) Manual / bedside procedures

6. Feeding evaluation by a speech-language therapist – hands-on testing of latch, suck, and swallow helps prevent aspiration and guides feeding aids for babies with cleft palate. AccessPediatrics

7. Bedside oximetry during feeds – quick pulse-ox monitoring checks for desaturation that suggests airway compromise from choanal atresia or epiglottic problems. AccessPediatrics

8. Flexible nasoendoscopy – a thin scope passed through the nose lets specialists see the posterior choanae and the epiglottis directly. This confirms blockage or bifid anatomy. AccessPediatrics

9. Audiology screening – bedside otoacoustic emissions (OAE) or automated brainstem tests are important because cleft palate increases ear disease risk. AccessPediatrics

10. Developmental screening – simple standardized checklists at well-baby visits catch delays early if thyroid treatment was late; early therapy can be started promptly. GARD Information Center

C) Laboratory and pathological tests

11. Newborn screening heel-prick test – high TSH with low T4 confirms congenital hypothyroidism and prompts immediate levothyroxine therapy. GARD Information Center

12. Serum thyroid panel – full TSH, free T4, and sometimes total T4/T3 help dose and monitor therapy over time. GARD Information Center

13. Thyroglobulin level – very low or absent thyroglobulin suggests athyreosis (no thyroid tissue), supporting imaging findings. AccessPediatrics

14. Genetic testing of FOXE1 – sequencing finds biallelic pathogenic variants and confirms the diagnosis; testing parents clarifies carrier status. Clinical labs and the NIH GTR list available tests. NCBI

15. Variant interpretation and gene panel – if single-gene testing is negative, a congenital hypothyroidism gene panel or exome test may detect rare regulatory or structural changes involving FOXE1. Prevention Genetics

16. Family studies – segregation testing shows the variant pattern within a family, confirming autosomal-recessive inheritance and guiding counseling. Karger Publishers

D) Electrodiagnostic tests

17. Automated auditory brainstem response (A-ABR) – an electrical test of hearing pathways used in cleft-palate care and newborn programs to ensure hearing is adequate for speech development. AccessPediatrics

18. Electrocardiogram (ECG) when clinically indicated – severe, untreated hypothyroidism may cause bradycardia or low-voltage changes; ECG documents rhythm and supports safe anesthesia planning for cleft surgery. (General CH practice.) AccessPediatrics

E) Imaging and endoscopic tests

19. Thyroid ultrasound – looks for thyroid tissue in the normal neck position and measures size; in this syndrome, the gland is often absent or small. NCBI

20. Radionuclide thyroid scan (scintigraphy) – shows functioning thyroid tissue or ectopic location; uptake is absent in athyreosis. CT or MRI of the nose and skull base may be added to map choanal atresia for surgical planning; laryngoscopy confirms a bifid epiglottis. ScienceDirect+1

Non-pharmacological treatments (therapies & other supports)

These actions do not replace thyroid hormone. They add practical safety and developmental support that families and clinicians use alongside L-T4.

1. Immediate newborn thyroid replacement plan (care pathway).
   Purpose: start L-T4 quickly (same day the diagnosis is confirmed) and set up frequent follow-up.
   Mechanism: standard neonatal congenital hypothyroidism (CH) management pathways ensure dose, monitoring and targets (normalize T4 in days and TSH in about 2 weeks). NCBI+1

2. Newborn screening to diagnosis handoff.
   Purpose: make sure an abnormal screen becomes a confirmed diagnosis and treatment within 2 weeks of life.
   Mechanism: CH programs call for rapid confirmatory testing and immediate L-T4 once CH is verified. AAP Publications+1

3. Craniofacial/ENT team care.
   Purpose: manage cleft palate, possible choanal atresia, feeding and airway issues.
   Mechanism: coordinated surgery/timing, airway safety, and feeding strategies improve growth, speech, and breathing. PubMed+1

4. Palatal obturator or specialized feeding devices.
   Purpose: help babies with cleft palate feed safely and gain weight before repair.
   Mechanism: temporarily seals palatal gap; reduces nasal regurgitation and aspiration risk. National Organization for Rare Disorders

5. Early speech-language therapy.
   Purpose: support speech and feeding skills after palate repair and during development.
   Mechanism: targeted exercises and strategies reduce hypernasality and improve articulation in cleft palate. National Organization for Rare Disorders

6. Lactation and nutrition support.
   Purpose: ensure adequate calories and growth in the first months.
   Mechanism: teach positioning, paced feeding, high-calorie strategies; coordinate with palate team. National Organization for Rare Disorders

7. Developmental surveillance & early intervention.
   Purpose: track milestones and provide therapies promptly if delays appear.
   Mechanism: regular developmental screening with referrals for PT/OT/SLP as needed; thyroid normalization supports brain development. NCBI

8. Ongoing TSH and free T4 monitoring schedule.
   Purpose: keep thyroid levels in the target range to protect growth and neurodevelopment.
   Mechanism: labs every 2–4 weeks initially, then spacing out as stable; dose adjusts with weight. Liebert Publishing+1

9. Medication administration training for caregivers.
   Purpose: prevent under- or over-treatment.
   Mechanism: show how to crush/disperse tablets, give on an empty stomach, and avoid absorption interactions (e.g., iron/calcium around dosing). FDA Access Data

10. Hearing screening and follow-up.
    Purpose: identify hearing issues that can accompany craniofacial anomalies and affect language.
    Mechanism: early audiology tests and interventions (e.g., tubes, hearing devices) as indicated. National Organization for Rare Disorders

11. Dental and oral health care.
    Purpose: manage feeding/oral-motor issues and dentition after cleft repair.
    Mechanism: pediatric dental follow-up guides hygiene, eruption, and orthodontic planning. National Organization for Rare Disorders

12. Airway monitoring (choanal atresia/breathing).
    Purpose: ensure safe breathing during sleep and illness.
    Mechanism: ENT evaluation, sleep studies when needed, and early surgical relief if obstruction present. PubMed

13. Growth tracking with thyroid targets.
    Purpose: ensure normal height/weight/head circumference trajectories.
    Mechanism: growth charts plus thyroid labs drive timely dose adjustments. NCBI

14. Family genetic counseling.
    Purpose: explain autosomal recessive inheritance, testing options, and recurrence risk.
    Mechanism: discuss FOXE1 testing and implications for future pregnancies. NCBI

15. Psychosocial support.
    Purpose: reduce stress and improve adherence in families coping with a rare disorder.
    Mechanism: social work, parent groups, and reliable education materials. National Organization for Rare Disorders

16. School-age learning support.
    Purpose: optimize academic progress.
    Mechanism: 504/IEP plans if needed; continued thyroid control helps attention and cognition. NCBI

17. Transition-of-care planning (teen → adult).
    Purpose: maintain lifelong thyroid care and medication continuity.
    Mechanism: create an adult-care plan with targets, labs, and prescriptions. NCBI

18. Perioperative planning for palate/ENT surgery.
    Purpose: ensure euthyroid state for anesthesia and healing.
    Mechanism: pre-op labs and temporary dose timing to keep T4 steady. FDA Access Data

19. Iodine exposure awareness (not a treatment).
    Purpose: avoid misattributing hypothyroidism to iodine issues when thyroid is absent.
    Mechanism: clarify that athyreosis means iodine will not “restart” a missing gland; therapy is L-T4. Liebert Publishing

20. Reliable medication supply planning.
    Purpose: prevent gaps in therapy.
    Mechanism: keep refills ahead, know equivalent brands/strengths, and avoid sudden product switches without labs. FDA Access Data

---

Drug treatment

Only one drug class is disease-modifying: Levothyroxine (L-T4). It replaces the missing thyroid hormone. Liothyronine (T3) alone is not recommended in infants with CH; expert guidelines and FDA labeling center care on L-T4. Liebert Publishing+2NCBI+2

Levothyroxine (L-T4) — neonatal & pediatric replacement (tablets)
Class: Thyroid hormone (T4) replacement.
Dose & timing: Start 10–15 μg/kg/day orally as soon as CH is confirmed (often ≈ 50 μg/day in full-term neonates), given once daily, ideally on an empty stomach; adjust by labs and growth. Aim to normalize serum T4 within days and TSH within about 2 weeks. AAP Publications+2AAP Publications+2
Purpose: Replace absent thyroid hormone to support brain myelination, growth, and metabolism. Early, adequate dosing prevents intellectual disability and growth failure. Liebert Publishing
Mechanism: Synthetic T4 converts peripherally to T3, binding nuclear thyroid-hormone receptors to regulate gene transcription and energy metabolism in the brain and body. FDA Access Data
How to give: Crush tablet, mix with a small amount of water/breast milk, give consistently; avoid co-administration with iron, calcium, soy formulas near the dose to prevent poor absorption. FDA Access Data
Side effects if over-treated: Irritability, poor sleep, fast heart rate, diarrhea, weight loss; long-term excessive dosing may affect bone. Under-treatment risks poor growth and neurodevelopmental harm. Monitor TSH and free T4 per pediatric protocols. FDA Access Data+1
Regulatory evidence: Multiple FDA-approved L-T4 products (e.g., Synthroid®, Levo-T®, Levoxyl®) carry labeling for congenital hypothyroidism in neonates and children. FDA Access Data+2FDA Access Data+2

Levothyroxine (L-T4) — injection (hospital use only, rare)
Class: Thyroid hormone (T4) replacement for IV use.
Use case: When oral dosing is temporarily impossible (e.g., severe GI intolerance, peri-operative NPO), clinicians may use parenteral levothyroxine and convert back to oral as soon as feasible. Dosing is individualized by specialists. FDA Access Data+1
Mechanism/purpose/risks: Same as oral L-T4; IV dosing requires careful monitoring to avoid over-replacement. FDA Access Data

Why not list 20 “drug treatments”? For athyreosis, no other medicines correct the hormone deficit. Adding “extra” drugs would be off-label and not evidence-based for infants with CH from absent thyroid. Authoritative pediatric guidelines specify L-T4 monotherapy as standard of care. Liebert Publishing+1

---

Dietary “molecular” supplements

None of these replace L-T4, and most have no proven outcome benefit in athyreosis. They’re listed only as adjunctive nutrition when clinically indicated—always discuss with your clinician.

1. Iodine (context only).
   Description: Essential for thyroid hormone synthesis, but not helpful when the thyroid is absent. Avoid excessive iodine exposures in infants. Dose is not used to treat athyreosis. Liebert Publishing

2. Iron (for deficiency).
   Description: Iron deficiency can impair development and also reduces L-T4 absorption if given together. If deficient, clinicians treat with iron but separate from L-T4 by several hours. FDA Access Data

3. Calcium/Vitamin D (bone health as child grows).
   Description: Useful for routine pediatric bone health if dietary intake is low. Do not give near L-T4 dosing because calcium interferes with absorption. FDA Access Data

4. DHA/ARA (long-chain polyunsaturated fatty acids).
   Description: Included in many infant formulas for neurodevelopmental support; not a thyroid therapy. Liebert Publishing

5. Zinc.
   Description: Important for growth and immunity; consider only when dietary intake is poor or labs indicate deficiency. No evidence it changes CH outcomes. Liebert Publishing

6. Selenium.
   Description: Selenium-dependent deiodinases convert T4→T3. Supplementation is not standard for CH due to athyreosis and is not a substitute for L-T4. Liebert Publishing

7. Protein-dense complementary foods (later infancy).
   Description: Support catch-up growth once solids start; emphasizes whole foods, not powders. Liebert Publishing

8. Iodine-adequate maternal diet (breastfeeding parent).
   Description: Ensures appropriate iodine in breast milk for the parent’s thyroid; infant still requires L-T4. Liebert Publishing

9. Avoid soy timing near the dose.
   Description: Soy formulas can reduce L-T4 absorption; if used, separate feeding and dose. FDA Access Data

10. General infant micronutrient sufficiency.
    Description: Follow standard pediatric guidance for vitamins/minerals if indicated; none replace L-T4. Liebert Publishing

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved immune boosters, regenerative medicines, or stem-cell drugs that restore a missing thyroid in infants. Research into thyroid development and FOXE1 biology continues, but clinical care today remains L-T4 plus craniofacial/ENT management. Any products marketed as “thyroid regeneration” for babies should be avoided. Liebert Publishing+1

To align with your format request, here are six brief, factual statements instead of drug entries:

• No approved stem-cell therapy for congenital athyreosis. L-T4 remains standard. Liebert Publishing

• No gene therapy for FOXE1 variants in clinical care. Frontiers

• No immune “boosters” correct hormone absence. Avoid non-evidence marketing. Liebert Publishing

• IV L-T4 may be used only when oral dosing is temporarily impossible. FDA Access Data

• T3-only therapy is not recommended in neonatal CH. Liebert Publishing

• Clinical trials & registries evolve; families should discuss research participation with specialists. NCBI

---

Surgeries (procedures & why they’re done)

1. Cleft palate repair (palatoplasty).
   Why: close the palatal gap to improve feeding, speech, middle-ear function, and growth. Timing and technique individualized by craniofacial team. National Organization for Rare Disorders

2. Choanal atresia repair (if present).
   Why: open blocked posterior nasal passages to ensure safe nasal breathing. May require stenting and careful follow-up. PubMed

3. Myringotomy with ear tubes (as needed).
   Why: reduce ear effusions and infections common with cleft-palate eustachian tube dysfunction; supports hearing and speech. National Organization for Rare Disorders

4. Secondary speech surgery/velopharyngeal procedures (select cases).
   Why: correct persistent velopharyngeal insufficiency and hypernasal speech after initial repair. National Organization for Rare Disorders

5. Orthognathic/orthodontic procedures (later childhood/teen).
   Why: address maxillofacial growth and occlusion issues associated with cleft repair and craniofacial development. National Organization for Rare Disorders

---

Preventions

1. Do not miss doses of L-T4; set alarms and keep spare supply. Liebert Publishing

2. Separate L-T4 from iron/calcium/soy by several hours to avoid poor absorption. FDA Access Data

3. Attend all lab checks (TSH, free T4) on schedule. Liebert Publishing

4. Keep a written dose plan that updates with weight changes. NCBI

5. Maintain airway safety if choanal atresia/obstruction suspected—seek ENT promptly. PubMed

6. Vaccinate on time per national schedules (no CH-specific restrictions). Liebert Publishing

7. Plan surgery when euthyroid (check labs before elective procedures). FDA Access Data

8. Use reliable brands/strengths and avoid unplanned switching without labs. FDA Access Data

9. Regular hearing and speech follow-up after palate care. National Organization for Rare Disorders

10. Genetic counseling for family planning and understanding recurrence risk. NCBI

---

When to see a doctor (or go now)

• Newborn period: immediately after an abnormal screen or once CH is confirmed—start L-T4 right away. AAP Publications

• Any time the infant seems excessively sleepy, feeds poorly, constipated, cold, or shows slowed growth—possible under-treatment. NCBI

• If very irritable, sweating, fast heart rate, poor weight gain—possible over-treatment. FDA Access Data

• Before surgeries (palate/ENT): check labs and dosing. FDA Access Data

• Ongoing: keep scheduled lab visits to maintain targets across infancy and childhood. Liebert Publishing

---

What to eat and what to avoid

Eat: normal, age-appropriate infant diet guided by your pediatrician; adequate calories and protein for growth; later, balanced family diet. Breastfeeding is welcome. Liebert Publishing

Avoid around the L-T4 dose (separate by hours): iron drops, calcium supplements, calcium-fortified products, and soy feeds—these lower L-T4 absorption if given together. FDA Access Data

Remember: food is for nutrition; it cannot replace the missing thyroid. L-T4 is essential. Liebert Publishing

---

Frequently asked questions

1) Is this the same as “Bamforth–Lazarus syndrome”?
Yes. That name is commonly used for FOXE1-related athyreosis with cleft palate and spiky hair. National Organization for Rare Disorders+1

2) What gene is involved?
Often FOXE1. Variants disrupt thyroid and palate formation in the embryo. PubMed

3) How common is it?
Very rare; only a small number of families reported worldwide. National Organization for Rare Disorders

4) Is it inherited?
Usually autosomal recessive: both parents carry one variant; each pregnancy has a 25% chance to be affected. NCBI

5) What is the main treatment?
Daily levothyroxine (L-T4) started as soon as CH is confirmed, with regular blood tests to adjust the dose. AAP Publications

6) What dose do babies start on?
Guidelines recommend 10–15 μg/kg/day (often 50 μg/day for a full-term neonate), then adjust. NCBI+1

7) How quickly does it work?
Free T4 usually normalizes in a few days; TSH often normalizes within about 2 weeks if dosing and absorption are good. NCBI

8) Why do we crush the tablet and mind the timing?
Crushed tablets are easier for infants; iron, calcium, and soy near the dose reduce absorption—so separate them by several hours. FDA Access Data

9) Do we ever use T3 (liothyronine) in babies?
Not as primary therapy for congenital hypothyroidism; expert guidance centers on L-T4 alone. Liebert Publishing

10) Will surgery fix the hormone problem?
No. Surgery repairs the palate or airway; L-T4 treats the hormone deficiency. National Organization for Rare Disorders

11) Can iodine supplements cure it?
No. Iodine is raw material for a thyroid gland, but in athyreosis the gland is absent—only L-T4 provides the hormone. Liebert Publishing

12) Are there stem-cell or gene therapies?
None are approved for this condition. Research is ongoing; talk with your specialist about registries or future options. Frontiers

13) What happens if we miss doses?
Persistent under-treatment risks poor growth and neurodevelopment. Call your team for catch-up guidance and lab checks. Liebert Publishing

14) Is long-term outlook good with treatment?
Yes—most children do well with early, adequate L-T4 and proper cleft/ENT care. Liebert Publishing

15) Where can I read more?
Authoritative summaries: Orphanet/NORD for Bamforth–Lazarus, AAP/ESPE/ATA for CH, and FDA labels for specific L-T4 products. FDA Access Data+4Orpha+4National Organization for Rare Disorders+4

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 16, 2025.